News Opinion Editor's Corner Olympic Hearts: Screening for CVD Among Team USA’s Athletes Michael O'Riordan July 31, 2024
News Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia Michael O'Riordan May 30, 2024
News Conference News HRS 2024 Goal of Arrhythmia Care in Athletes is a Return to Play: HRS Consensus Michael O'Riordan May 23, 2024
News Daily News Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies Michael O'Riordan December 19, 2023
News Daily News Family History of CVD? Low PUFA Intake May Add to Risk Michael O'Riordan December 12, 2023
News Conference News ESC 2023 ESC Cardiomyopathy Guidelines Span Range of Phenotypes Yael L. Maxwell August 31, 2023
News Daily News Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death Michael O'Riordan July 07, 2023
News Conference News ACC 2023 Studies Support (Careful) Return to Sport for Athletes With Genetic Conditions Michael O'Riordan March 07, 2023
News Conference News ESC 2022 ESC Revamps Guidelines on Ventricular Arrhythmias, Sudden Cardiac Death Todd Neale September 02, 2022
News Conference News ESC 2022 Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE Michael O'Riordan August 31, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022
News Daily News Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution Michael O'Riordan August 11, 2022
News Conference News EAS 2022 Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol Michael O'Riordan May 26, 2022
News Conference News EAS 2022 FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses Michael O'Riordan May 26, 2022
News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News ACC 2022 Managing AF Patients Undergoing PCI—Some Lingering Questions Michael O'Riordan April 12, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Features Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path Michael O'Riordan January 17, 2022